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ABSTRACT
Objective The Pragmatic Ischaemic Thrombectomy
Evaluation (PISTE) trial was a multicentre, randomised,
controlled clinical trial comparing intravenous
thrombolysis (IVT) alone with IVT and adjunctive intra-
arterial mechanical thrombectomy (MT) in patients who
had acute ischaemic stroke with large artery occlusive
anterior circulation stroke conﬁrmed on CT angiography
(CTA).
Design Eligible patients had IVT started within
4.5 hours of stroke symptom onset. Those randomised to
additional MT underwent thrombectomy using any
Conformité Européene (CE)-marked device, with target
interval times for IVT start to arterial puncture of
<90 min. The primary outcome was the proportion of
patients achieving independence deﬁned by a modiﬁed
Rankin Scale (mRS) score of 0–2 at day 90.
Results Ten UK centres enrolled 65 patients between
April 2013 and April 2015. Median National Institutes
of Health Stroke Scale score was 16 (IQR 13–21).
Median stroke onset to IVT start was 120 min. In the
intention-to-treat analysis, there was no signiﬁcant
difference in disability-free survival at day 90 with MT
(absolute difference 11%, adjusted OR 2.12, 95% CI
0.65 to 6.94, p=0.20). Secondary analyses showed
signiﬁcantly greater likelihood of full neurological
recovery (mRS 0–1) at day 90 (OR 7.6, 95% CI 1.6 to
37.2, p=0.010). In the per-protocol population (n=58),
the primary and most secondary clinical outcomes
signiﬁcantly favoured MT (absolute difference in mRS
0–2 of 22% and adjusted OR 4.9, 95% CI 1.2 to 19.7,
p=0.021).
Conclusions The trial did not ﬁnd a signiﬁcant
difference between treatment groups for the primary end
point. However, the effect size was consistent with
published data and across primary and secondary end
points. Proceeding as fast as possible to MT after CTA
conﬁrmation of large artery occlusion on a background
of intravenous alteplase is safe, improves excellent
clinical outcomes and, in the per-protocol population,
improves disability-free survival.
Trial registration number NCT01745692; Results.
BACKGROUND
Recanalisation and reperfusion of the brain are
associated with greater chance of favourable
outcome after acute ischaemic stroke.1 Intravenous
thrombolysis with recombinant tissue plasminogen
activator (rtPA) improves the likelihood of recanali-
sation, and treatment within 4.5 hours of stroke
onset is associated with signiﬁcantly increased like-
lihood of recovery without disability by 90 days
after stroke.2 However, among those patients with
large artery occlusion (LAO) in the carotid circula-
tion (occlusion of the intracranial internal carotid
artery (ICA), or proximal middle cerebral artery
(MCA)), intravenous rtPA is able to effect recanali-
sation in only a small proportion of patients,3 and
despite intravenous thrombolytic therapy, a high
proportion of patients with LAO stroke die or
remain disabled.
Intra-arterial treatment of stroke, initially with
thrombolytic drugs and then with endovascular
devices designed to fragment or extract the causa-
tive thrombus, has been investigated over many
years. Devices developed in the early 2000s
achieved higher rates of recanalisation, but clinical
outcomes were not clearly superior to those
achieved by intravenous thrombolysis (IVT)
alone.4 5 The third Interventional Management of
Stroke trial (IMS-3)6 found no difference in
outcome between patients treated with IVT alone
compared to IVT with additional intra-arterial
treatment. The IMS-3 trial used predominantly
older devices that were found subsequently to be
less effective than the later stent-retriever devices7 8
and did not have non-invasive vascular imaging to
establish the presence of treatable LAO in the
majority of its patients. The trial also identiﬁed a
strongly time-dependent likelihood of recovery to
independence, emphasising the importance of fast
intervention times.9
A series of ﬁve trials using angiographic imaging
and mechanical thrombectomy (MT) predomin-
antly using stent-retrievers reported positive results
in 2015 in favour of MT,10–14 with results from
two further trials presented. All trials were con-
ducted at expert stroke centres with highly efﬁcient
systems for delivery of MT and experience in this
modality of treatment. Whether these ﬁndings are
generalisable to countries with different healthcare
systems, such as the UK, was unclear.
We undertook the PISTE trial to evaluate the
efﬁcacy of MT in addition to best medical therapy,
including IVT, compared to best medical therapy
38 Muir KW, et al. J Neurol Neurosurg Psychiatry 2017;88:38–44. doi:10.1136/jnnp-2016-314117
Cerebrovascular disease
alone. Recruitment to the trial was halted after review of other
trial data.
METHODS
PISTE was a multicentre, randomised, controlled, parallel group
trial of prospective, randomised, open, blinded end point evalu-
ation (PROBE) design (clinicaltrials.gov NCT01745692).
Ethical approvals were given by the Scotland A Research Ethics
Committee (12/SS/0059) and the National Research Ethics
Service Committee North East-Newcastle & North Tyneside 2
(12-NE-0315). Adult patients ≥18 years were eligible if present-
ing with acute supratentorial ischaemic stroke and eligible for
IVT started within 4.5 hours of symptom onset. If non-invasive
angiographic imaging with CT angiography (CTA) or magnetic
resonance angiography showed occlusion of the intracranial
ICA, M1 segment of the MCA or a single M2 MCA branch,
patients were eligible for randomisation. We excluded patients
with contraindications to IVT, life expectancy limited to
<90 days, with chronic extracranial ICA occlusion or with
extensive early hypodensity on non-contrast CT brain involving
more than one-third of the MCA territory. All patients had IVT
initiated at the neurovascular centre.
Neurointerventional centres were required to have a
minimum of two experienced operators—with ≥10 thrombec-
tomy procedures per centre for acute stroke treatment in the
preceding 18 months, and to have extensive experience of other
intracranial endovascular procedures—with centre volumes
exceeding 120 per annum for the past 3 years and individual
operators exceeding 120 in total; of which, at least 60 were in
the preceding 18 months. Intervention was to be initiated as fast
as possible after conﬁrming eligibility, and a maximum of
90 min from start of IVT to start of the MT procedure (groin
puncture) was permitted. The target vessel should have been
cannulated within a maximum of 6 hours of symptom onset.
Patients were randomised 1:1 to receive best medical therapy
with IVT alone, or undergo additional (adjunctive) MTwith any
operator-selected CE-marked device approved for intracranial
clot removal. Allocation used a minimisation algorithm, includ-
ing age group, stroke severity on the National Institutes of
Health Stroke Scale (NIHSS) and symptom onset-to-treatment
time. Randomisation was conducted using an interactive
voice-response system managed by the Robertson Centre for
Biostatistics, University of Glasgow.
The primary outcome was deﬁned as the proportion of
patients achieving independence at day 90 after stroke onset,
based on a score of 0, 1 or 2 on the modiﬁed Rankin Scale
(mRS).15 16 Day 90 outcomes were assessed by site staff blind to
treatment allocation. We deﬁned secondary outcome measures
as excellent recovery (mRS score 0–1); change in the distribu-
tion of scores on the mRS; early major neurological improve-
ment (improvement by ≥8 points on the NIHSS or NIHSS of 0
or 1 at 24 hours after stroke); ‘home time’ (time spent in usual
residence between stroke onset and day 90);17 the proportion of
patients with recanalisation on the IST-3 CTA scale18 at
24 hours; mortality; and the incidence of symptomatic intracer-
ebral haemorrhage (SICH) deﬁned using SITS-MOST criteria19
as a parenchymal haematoma type 220 on CT or MRI brain at
24–36 hours and a clinical worsening of ≥4 points on the
NIHSS.
All imaging studies were uploaded to a central imaging reposi-
tory, anonymised, validated and loaded into a web-based
viewing system (Systematic Image Review System-2, SIRS-221)
for reading by three neuroradiologists blind to treatment alloca-
tion as well as all clinical data as a ‘core lab’ interpretation.
Extent of early ischaemic change on brain imaging was deﬁned
by the Alberta Stroke Programme Early CT score (ASPECTS).22
The site of vessel occlusion at baseline was deﬁned on CT
angiography (CTA). Collateral circulation was graded as poor,
moderate or good.11 The extent of thrombus was graded using
the clot burden scale.23 Recanalisation at the end of the proced-
ure among those allocated additional MT was graded by the
modiﬁed Thrombolysis in Cerebral Infarction (mTICI) scale
with reperfusion success deﬁned as mTICI score 2b or
3. Recanalisation at 24 hours was assessed on repeat CTA using
the third International Stroke Trial (IST-3) CTA score.18
The intention-to-treat (ITT) population consists of all patients
randomised in the trial, and the per-protocol population consists
of all patients in the ITT population who did not have any
major protocol violation identiﬁed prior to database lock.
The primary efﬁcacy analysis is the comparison of the
primary outcome mRS ≤2 at day 90 between treatment groups
using logistic regression adjusting for the minimisation factors
used in the randomisation. These were age group (≤80 or >80),
NIHSS score (6–12, 13–19, 20–42), time to rtPA (<3 hours,
≥3 hours) and study site. Analyses were performed identically
for ITT and per-protocol populations. For the analysis, sites
recruiting fewer than 10 patients were grouped together. Binary
secondary outcomes were analysed analogously. mRS distribu-
tion was analysed using proportional odds logistic regression
instead of logistic regression, additionally adjusting for prestroke
(baseline) mRS. The number of days in usual residence between
day 0 and day 90 was analysed using exact permutation tests.
The statistical analysis plan was agreed prior to database lock
and unblinding. Statistical analyses have been carried out using
Figure 1 CONSORT ﬂow chart
showing disposition of trial
participants. CTA, CT angiography; ITT,
intention to treat; IVT, intravenous
thrombolysis; MCA, middle cerebral
artery; mRS, modiﬁed Rankin Scale;
MT, mechanical thrombectomy.
Muir KW, et al. J Neurol Neurosurg Psychiatry 2017;88:38–44. doi:10.1136/jnnp-2016-314117 39
Cerebrovascular disease
R V.3.0.1 (R Foundation for Statistical Computing, Vienna,
Austria). The signiﬁcance level for the primary analysis is 0.05.
The original sample size calculation assumed that 44% of
intravenous-treated and 57% of MT-treated patients would
achieve mRS 0–2, based on the CTA subgroup of IMS-3.24 This
yielded a sample size of ∼200 participants per group for 80%
power, p=0.05. Since a more conservative 10% absolute
increase in independent recovery would have been clinically
worthwhile, a sample size of 400 participants per group was ori-
ginally planned (assuming 45% and 55% mRS 0–2 in the two
groups).
RESULTS
Between April 2013 and April 2015, 65 patients were recruited
at 10 centres in the UK. Trial recruitment was suspended in
April 2015 following presentation of other relevant thrombec-
tomy trial results and ended in June 2015. Seven patients were
excluded from a per-protocol analysis based on major protocol
deviations (ﬁgure 1). IVT alone was allocated to 32 patients and
IVT with additional MT in 33. Two patients were lost to
follow-up at day 90, with no mRS data available, both in the
IVT-only group. Major demographic and medical history factors
are detailed in table 1.
Those randomised to receive MT were older, more often
female, had more severe strokes, higher prevalence of some vas-
cular risk factors (diabetes, atrial ﬁbrillation) and a higher pro-
portion had prestroke impairment on estimated mRS; a higher
proportion had good collateral score and favourable ASPECT
score (table 1).
Procedural outcomes
Procedural timelines (table 1) were within protocol-
recommended parameters. IVTwas started a median of 120 min
(IQR 93–150 min) after onset of symptoms. Among those allo-
cated MT, interventional times were short and consistent with
protocol recommendations. Total time from symptom onset to
end of MT procedure was median 251 min.
Stent-retriever devices were used ﬁrst in 68% of procedures
and aspiration devices in 32%. General anaesthesia was used in
10/32 (31%) of patients and sedation in 22/32 (69%). In 25/32
(81%) patients (one patient did not undergo MT as rando-
mised), a single device was used. TICI 2b-3 reperfusion at the
end of MT procedure was achieved in 26/30 assessable immedi-
ate postprocedure angiograms (87%).
CTA at ∼24 hours was completed in 51/65 (78%) of patients
and showed reduced likelihood of vessel occlusion among those
randomised to additional MT compared to those treated with
IVT alone. The proportion with an IST-3 score >1 (at least
partial ﬁlling of major branches of the target vessel) was 77% vs
38%, and the proportion with IST3 score of 4 (complete
patency, normal appearance) was 69% vs 33% (OR 0.18, 95%
CI 0.05 to 0.64, p=0.008 in proportional odds regression of
IST3 scores).
Primary outcome
In the ITT population, the difference in the proportion achiev-
ing mRS 0–2 at day 90 (51% vs 40%, adjusted OR 2.12, 95%
CI 0.65 to 6.94, p=0.204) was not signiﬁcant. In the per-
protocol population, however, there was a signiﬁcant effect in
Table 1 Demographics, medical history, stroke characteristics and
treatment process times
Intravenous rtPA
(IVT) IVT+MT
n 32 33
Age, years, mean±SD 64±16 67±17
>80 years, n (%) 3 (9%) 6 (18%)
Male, n (%) 16 (50%) 13 (39%)
Estimated prestroke mRS
0 28 (88%) 27 (82%)
1 1 (3%) 5 (15%)
≥2 3 (9%) 1 (3%)
Smoker (current), n (%) 3 (9%) 4 (12%)
MI or IHD, n (%) 6 (19%) 4 (12%)
Previous stroke, n (%) 2 (6%) 3 (9%)
Diabetes, n (%) 6 (19%) 11 (33%)
Hypertension, n (%) 17 (53%) 17 (52%)
Atrial fibrillation, n (%) 8 (25%) 15 (46%)
Prestroke antithrombotic therapy, n
Aspirin 3 (9%) 2 (6%)
Clopidogrel 0 1 (3%)
Warfarin 2 (6%) 1 (3%)
Direct oral anticoagulant 0 3 (9%)
Glucose, mmol/L (mean±SD) 7.3 (3.4) 8.0 (3.2)
Pretreatment systolic/diastolic BP
mm Hg (mean±SD)
144/83 (25/18) 147/77 (23/15)
NIHSS median, range 14 (6–29) 18 (6–24)
ASPECTS median, range 9 (2–10) 9 (4–10)
0–4, n (%) 1 (3%) 1 (3%)
5–7, n (%) 9 (28%) 6 (18%)
8–10, n (%) 22 (69%) 26 (79%)
CTA occlusion site, n (%)
ICA T/L±M1±M2 6 (19%) 4 (14%)
MCA M1±M2 21 (65%) 22 (76%)
MCA M2 5 (16%) 3 (10%)
Collateral score, n (%)
Good 12 (40%) 18 (55%)
Moderate 12 (40%) 10 (30%)
Poor 6 (20%) 5 (15%)
Extracranial ICA occlusion present, n
(%)
1 (3%) 1 (3%)
Clot burden score, median (IQR) 6 (4, 7) 7 (4, 8)
Process times, min, median (IQR)
Symptom onset to IVT start 120 (62, 238) 120 (61, 242)
Symptom onset to randomisation 150 (88, 268) 150 (78, 271)
IVT start to groin puncture 82 (28, 140)
Randomisation to groin puncture 58 (12, 87)
Groin puncture to device removal 49 (15, 137)
Total time, onset to procedure end 251 (181, 390)
Poststroke antithrombotic therapy, n
Aspirin 17 (53%) 20 (61%)
Clopidogrel 10 (31%) 11 (33%)
Warfarin 1 (3%) 2 (6%)
Direct oral anticoagulant 2 (6%) 3 (9%)
ASPECTS, Alberta Stroke Programme Early CT Score; BP, blood pressure; CTA, CT
angiography; ICA, internal carotid artery; IHD, ischaemic heart disease; IVT,
intravenous thrombolysis; MCA, middle cerebral artery; MI, myocardial infarction;
mRS, modified Rankin Scale; MT, mechanical thrombectomy; NIHSS, National
Institutes of Health Stroke Scale; rtPA, recombinant tissue plasminogen activator.
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favour of adjunctive MT after adjustment for minimisation vari-
ables, with an absolute difference in the proportion achieving
mRS 0–2 at day 90 of 22% (57% vs 35%, OR 4.92, 95% CI
1.23 to 19.69, p=0.021) (table 2 and ﬁgure 2).
Secondary efﬁcacy outcomes
In the ITT population, there was a signiﬁcantly greater likelihood
of complete functional recovery (mRS 0–1) at day 90 with adjunct-
ive MT compared to IVT alone after adjustment (OR 7.63, 95%
CI 1.56 to 37.22, p=0.010). The difference in the distribution of
mRS scores at day 90 (OR 2.59, 95% CI 0.93 to 7.24, p=0.070)
did not reach signiﬁcance (ﬁgure 2A and table 2).
In the per-protocol population, there was signiﬁcantly greater
likelihood of excellent outcome and better distribution of mRS
scores at day 90 (ﬁgure 2B and table 2). The estimated number
needed to treat for one person to have mRS ≤2 at day 90 was
6.91 in the adjusted analysis.
No signiﬁcant difference in major early neurological recovery
was seen in either ITT or PP populations, nor in the number of
days spent in usual residence between stroke onset and day 90,
Table 2 Primary and secondary outcomes in ITT and per-protocol populations
ITT Per protocol
mRS 0–2 at day 90 OR 2.12 (0.65 to 6.94) p=0.204 OR 4.92 (1.23 to 19.69) p=0.021
Secondary outcomes
mRS 0–1 at day 90 OR 7.63 (1.56 to 37.22) p=0.010 OR 14.6 (2.11 to 101.5) p=0.005
mRS distribution OR 2.59 (0.93 to 7.24)* p=0.070 OR 4.47 (1.45 to 13.80)* p=0.009
Death OR 1.56 (0.29 to 8.40) p=0.599 OR 0.69 (0.10 to 4.68) p=0.697
Early major neurological improvement (NIHSS 0–1 or improved ≥8) OR 1.83 (0.54 to 6.25) p=0.321 OR 2.98 (0.76 to 11.65) p=0.106
Days in usual residence, days 0–90 68 vs 78.5 p=0.782† 58 vs 79 p=0.411†
SICH (SITS-MOST) 0 vs 0 p=1.000‡ 0 vs 0 p=1.000‡
PH1/2 ICH 1 vs 3 p=0.613‡ 0 vs 3 p=0.238‡
IST-3 angiographic score=4 at 24 hours OR 0.18 (0.05 to 0.64) p=0.008 OR 0.17 (0.04 to 0.64) p=0.009
*Adjusted for baseline (prestroke) mRS in addition to minimisation variables.
†p value from exact permutation test.
‡p value from exact Fisher test.
ITT, intention to treat; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; SICH, symptomatic intracerebral haemorrhage.
Figure 2 mRS distribution at day
90 in (A) ITT population and
(B) per-protocol population. ITT,
intention to treat; IVT, intravenous
thrombolysis; mRS, modiﬁed Rankin
Scale; MT, mechanical thrombectomy.
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although the direction of effects was consistently in favour of
the additional MT group (table 2).
Safety
In the ITT population, there were more deaths in the MT group
(7 vs 4), but mortality did not differ signiﬁcantly between IVT
alone and IVT+MT groups (table 2). In the IVT group, one
death was due to early brain swelling and three due to later
complications (pneumonia or acute myocardial infarction (MI)
22–28 days after randomisation). In the IVT+MT group, four
deaths were due to brain swelling and neurological deterioration
(two of these in cases where recanalisation was not achieved
and one in a patient excluded in the per-protocol analysis), one
death from acute MI, one from aspiration pneumonia within
the ﬁrst week and one death due to pneumonia occurred later
(27 days). There were no SICH events meeting SITS-MOST def-
inition. Other ICH and adverse events are detailed in table 3.
Three recurrent ischaemic stroke events in the MT group were
not considered related to thrombus extraction in any case: two
occurred 48–72 hours after the presenting event in patients with
atrial ﬁbrillation; the third occurred on the day of MT in a
patient also in atrial ﬁbrillation. The two patients with recurrent
ischaemic stroke post-MT were on antiplatelet therapy only at
the time of the event.
DISCUSSION
The PISTE trial was the only randomised controlled trial of MT
in which a policy of proceeding as rapidly as possible to inter-
vention on the basis of CTA conﬁrmation of relevant LAO was
pursued, in contrast to trials that either by protocol or in prac-
tice delayed endovascular treatment to assess the effects of IVT
(MR CLEAN and REVASCAT)10 14 or employed additional per-
fusion or intracranial collateral vessel imaging to select patients
(ESCAPE, EXTEND-IA, SWIFT-Prime11–13). The ﬁndings are
consistent with those reported from other clinical trials of MT.
While the primary end point was not signiﬁcant in the ITT
population, a signiﬁcantly greater proportion of patients allo-
cated MT achieved the important secondary end point of excel-
lent neurological recovery to mRS ≤1, and all major efﬁcacy
end points signiﬁcantly favoured MT in the per-protocol popu-
lation. The magnitude of estimated treatment effect was similar
to those reported in other recent trials of MT (table 4).25
Interventional procedures for acute ischaemic stroke have
been undertaken increasingly in healthcare systems that reim-
burse these procedures since regulatory approval of endovascu-
lar devices from the mid-2000s.26 In contrast, few procedures
have been undertaken in the UK, where interventional manage-
ment of stroke has been uncommon, except in a small number
of centres.
The efﬁcacy of thrombectomy for large artery occlusive
ischaemic stroke was ﬁrst shown in a randomised trial in MR
CLEAN10 and conﬁrmed by results from four subsequently pub-
lished trials (EXTEND-IA,12 ESCAPE,11 SWIFT-prime13 and
REVASCAT14). Like PISTE, these four trials, and also two
further endovascular trials that have been presented but not yet
published (THRACE and THERAPY), were terminated prema-
turely after interim review of data by trial data monitoring com-
mittees in response to the MR CLEAN results. We continued
recruitment to PISTE up until the presentation of THRACE in
April 2015 since PISTE addressed a subtly different question
compared to the other trials that had been published and MT
was not an accepted standard of care in the UK until April
2016. Early discontinuation of the trial led to small sample size,
which is likely to be the main factor in the lack of signiﬁcant dif-
ference between groups for the primary end point, since process
indicators do not suggest any signiﬁcant difference in speed of
intervention or effectiveness of the intervention (table 4). Our
results are consistent with the beneﬁt shown for MT in larger
trials, including a signiﬁcant increase in the proportion of
patients achieving excellent recovery. As with previous studies,
there were no safety issues, with respect to mortality, intracereb-
ral haemorrhagic events or general adverse events.
MR CLEAN and REVASCAT delayed MT initiation in
order to evaluate the effectiveness of intravenous rtPA—expli-
citly in the REVASCAT protocol, which stipulated a minimum
30 min delay in MT, and implicitly in MR CLEAN. Both
trials were characterised by early initiation of IVT but then
long delays to randomisation and intervention, and conse-
quently later reperfusion than the other three published trials.
Effect size estimates were somewhat lower. The three trials
that did not delay MT, and recommended proceeding as fast
as possible to intervention regardless of IVT, were more
selective and all reported larger effect sizes and shorter reper-
fusion times, but interpretation is confounded by the use in
each of these trials of additional advanced imaging selection
using perfusion imaging12 13 or ASPECTS+collateral imaging
scoring.11 Of the two unpublished trials, THRACE
Table 3 Serious adverse events
Intravenous
rtPA (IVT) IVT+MT
n 32 33
No. with any SAE 11 (34%) 15 (45%)
No. of SAEs reported 15 21
Probably or definitely related to
study procedures
3 2
Fatal SAEs 4 7
No. fatal SAEs <7 days after
onset
1 6
Fatal neurological events
<7 days after onset
1 4
Intracerebral haemorrhage events
Any ICH 3 3
SICH 0 0
ICH events on CT
HI1 or HI2 12 13
PH1 1 1
PH2 0 2
Non-ICH SAEs 12 18
Anaemia 0 1
MI/acute coronary syndrome 2 1
Gingival bleeding 1 0
Pneumonia 4 5
Brain swelling 2 4
Recurrent ischaemic stroke 0 3
Neurological deterioration,
not definitely ICH or swelling
0 1
Other 3 (CCF, UTI,
psychiatric)
3 (pulmonary embolism,
osteoarthritis, UTI)
CCF, congestive cardiac failure; HI1/HI2, haemorrhagic infarction types 1 or 2; ICH,
intracerebral haemorrhage; IV, intravenous; MI, myocardial infarction; MT, mechanical
thrombectomy; PH1/2, parenchymal haematoma types 1 or 2; rtPA, recombinant
tissue plasminogen activator; SAE, serious adverse event; SICH, symptomatic
intracerebral haemorrhage; UTI, urinary tract infection.
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predominantly used MRI for selection, and THERAPY used
assessment of clot burden (requiring clot length >8 mm on
CT). PISTE was the only trial to use simple imaging (CT and
CTA) and a policy of proceeding as fast as possible to MT
without additional imaging selection. Onset to reperfusion
time was accordingly short, and comparable to the ‘complex
imaging’ trials run in experienced MT centres.11–13
Previous trials have been based in well-organised regional or
national networks (REVASCAT and MR CLEAN), and/or have
selected sites that have signiﬁcant experience of MT in addition
to highly organised acute IVT services with rigorous centre cre-
dentialing.11 13 It was important to establish whether similar
effect sizes could be achieved in a healthcare setting where MT
was not regarded as ‘standard of care’ and where the supporting
networks were less developed. The ﬁndings of PISTE indicate
that effect sizes similar to those achieved in the other MT trials
are feasible within a less experienced organisational framework
and without complex imaging, although the trial relied upon
effective multidisciplinary teams within comprehensive stroke
centres.
While it is important to regard ﬁndings based on small
numbers with caution, the difference between the ITT and per-
protocol analyses of PISTE suggests that adherence to strict
patient selection criteria may be important in maximising the
efﬁcacy of MT. Those excluded from the per-protocol analysis
included one crossover to MT in the IVT-only arm, ﬁve patients
with inadequate assessment of preprocedure imaging (three
more extensive established ischaemic change than permitted;
one lack of vascular access to the target vessel due to extensive
extracranial arterial occlusion; one ineligible occlusion site) and
one patient with signiﬁcant prestroke disability.
Although recent individual patient data and group-level
meta-analyses, including the ﬁve published trials, have reﬁned
the effect size estimates and allowed some important subgroups
to be clariﬁed,25 there remain questions around generalisability,
notably whether there are sufﬁcient beneﬁts in some groups of
patients (eg, those with extensive early ischaemia, those ineli-
gible for IVT), the minimum organisational and training
requirements for safe and effective implementation, the role of
advanced imaging selection and the cost-effectiveness of MT.
Further clinical trials are required to investigate the limits of
effectiveness for MT and to provide additional information on
absolute effect sizes in different subgroups that will guide
service implementation.
While we did not ﬁnd signiﬁcant differences in the primary
outcome measure on ITT analysis, the secondary end point of
excellent recovery (mRS 0–1) was signiﬁcant in the ITT popula-
tion, all mRS-based outcomes were signiﬁcant in favour of MT
in the per-protocol population and the effect size estimates were
consistent with other trials. We therefore conclude that PISTE
conﬁrms the safety of a policy of adjunctive MT based on rela-
tively simple imaging (CT+CTA) and supports striking beneﬁt
of MT in patients with acute large anterior circulation artery
occlusive acute ischaemic stroke and the feasibility of such treat-
ment within the UK healthcare system with well-organised ser-
vices for delivery of IVT, but only limited prior experience of
thrombus extraction for acute stroke.
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